Version 1
: Received: 8 April 2024 / Approved: 9 April 2024 / Online: 10 April 2024 (09:22:02 CEST)
How to cite:
Kassab, M. Design of Lipid Nanoparticles of mRNA Vaccine against Respiratory Syncytial Virus by Bioinformatics in Egypt. Preprints2024, 2024040723. https://doi.org/10.20944/preprints202404.0723.v1
Kassab, M. Design of Lipid Nanoparticles of mRNA Vaccine against Respiratory Syncytial Virus by Bioinformatics in Egypt. Preprints 2024, 2024040723. https://doi.org/10.20944/preprints202404.0723.v1
Kassab, M. Design of Lipid Nanoparticles of mRNA Vaccine against Respiratory Syncytial Virus by Bioinformatics in Egypt. Preprints2024, 2024040723. https://doi.org/10.20944/preprints202404.0723.v1
APA Style
Kassab, M. (2024). Design of Lipid Nanoparticles of mRNA Vaccine against Respiratory Syncytial Virus by Bioinformatics in Egypt. Preprints. https://doi.org/10.20944/preprints202404.0723.v1
Chicago/Turabian Style
Kassab, M. 2024 "Design of Lipid Nanoparticles of mRNA Vaccine against Respiratory Syncytial Virus by Bioinformatics in Egypt" Preprints. https://doi.org/10.20944/preprints202404.0723.v1
Abstract
Background:
Respiratory syncytial virus[ RSV] is a lethal overwhelming defectiveness that influences people all over the world. The infection gets down in the lower respiratory tract and does not disperse to the remainder of the body.
The objective of the study:
Bioinformatics was used to create an mRNA vaccine against the Respiratory syncytial virus( RSV).
Methodology:
Lipid nanoparticle vaccines containing the Respiratory syncytial virus's surface fusion protein's mRNA were created for the current screening experimental investigation. Lipid nanoparticles[ LNP] with a particle size of around 90 nanometres that were created using the hot micro-emulsion process comprise the current vaccine delivery system. In stages 1 and 2 of clinical trials, the immunogenicity of the current mRNA RSV vaccine was evaluated.
Results:
The current vaccine demonstrated 81% immunogenicity in animal testing, but only 69% in stages 1 and 2 of clinical trials. Its side effects were manageable. The results persisted for a while. In the current trial, the vaccination proved effective as a preventative measure against RSV infection. The current immunization lacks antibody-dependent enhancement, which causes non-protective antibodies to develop. These non-neutralizing antibodies worsen infection by enhancing viral entrance and replication in the host cells, activating cytokines and the complement cascade through the production of immunological complexes, or both. However, the current LPN-RSV mRNA vaccine of the surface fusion protein resulted in the formation of potent neutralizing antibodies with persistent protection, especially for newborns and elderly individuals who get the ideal dose regimen.
Conclusion:
The invention of the LNP-mRNA RSV vaccine, which might prevent RSV-caused bronchiolitis and fatal pneumonia, made the current study promising
Public Health and Healthcare, Public Health and Health Services
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
